Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Thomas Spreter von Kreudenstein
Observed names:
T. Spreter von Kreudenstein,
Thomas Spreter Von Kreudenstein
Institution:
Zymeworks (Canada)
Observed institution:
Zymeworks (Canada)
OpenAlex ID:
A5045396651
Improving biophysical properties of a bispecific antibody scaffold to aid developability: Quality by molecular design
2013
·
Thomas Spreter Von Kreudenstein
, Eric Escobar-Carbrera
, et al.
·
mAbs
·
129
PDF
LC-MS characterization and purity assessment of a prototype bispecific antibody
2013
·
R. Jeremy Woods
, Michael Hongwei Xie
, et al.
·
mAbs
·
38
Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering
2013
·
Thomas Spreter Von Kreudenstein
, Paula I. Lario
, et al.
·
Methods
·
16
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics
2022
·
Florian Heinkel
, Meghan M. Verstraete
, et al.
·
mAbs
·
6
ZW1528, A Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
2025
·
M. Poffenberger
, P.P. Bhojane
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
3
Abstract 7318: ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
2025
·
Desmond Lau
, Peter Repenning
, et al.
·
Cancer Research
·
3
Abstract 6719: TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors
2024
·
Lisa Newhook
, Purva Bhojane
, et al.
·
Cancer Research
·
3
Abstract 5121: TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors
2023
·
Lisa Newhook
, Purva P. Bhojane
, et al.
·
Cancer Research
·
3
Late Breaking Abstract - ZW1528: A dual-targeting bispecific antibody to broadly suppress airway inflammation by inhibiting IL-4Ra and IL-33 pathways
2025
·
Blair Hardman
, Maya C. Poffenberger
, et al.
·
European Respiratory Journal
·
2
Abstract 3503: ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
2025
·
Nicole J. Afacan
, Patricia Zwierzchowski
, et al.
·
Cancer Research
·
2
Abstract 6716: DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancers
2024
·
Peter Repenning
, Desmond Lau
, et al.
·
Cancer Research
·
2
Abstract 2935: ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity
2023
·
Maya C. Poffenberger
, Jennifer L. Bishop
, et al.
·
Cancer Research
·
2
Abstract 2926: PROTECTTM, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action
2023
·
Anna von Rossum
, Genevieve Desjardins
, et al.
·
Cancer Research
·
2
1196 TriTCE Co-stim: a differentiated T cell engager platform with conditional cis CD28 co-stimulation is transferable to diverse targeting strategies
2025
·
Chayne L Piscitelli
, Diego Perez Escanda
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
2023
·
Lisa Newhook
, Purva Bhojane
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 2982: TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors
2023
·
Maya C. Poffenberger
, Meghan M. Verstraete
, et al.
·
Cancer Research
·
1
810 Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence
2026
·
Desmond Lau
, Scott Lien
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
853 Design of a next generation tumor targeted masked IL-12Fc for enhanced tolerability and localized anti-tumor activity
2025
·
Nichole Escalante
, Sifa Arrafi
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
2023
·
Meghan M Verstraete
, Maya Poffenberger
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 2942: ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors
2023
·
Nicole J. Afacan
, Chayne Piscitelli
, et al.
·
Cancer Research
ZW38, a bispecific CD3 x CD19 azymetric antibody to deplete human leukemic B cells by the “controlled” activation of T cells.
2015
·
Gordon Ng
, Nina Weisser
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
21
Citation count:
214
H-index:
4
I10-index:
3
Year
Topic
Type